Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review.
Sign Up to like & getrecommendations! Published in 2020 at "Neoplasma"
DOI: 10.4149/neo_2020_190801n701
Abstract: Apatinib (YN968D1) is a novel and highly selective tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2) and is approved as a third-line and subsequent-line treatment for advanced gastric adenocarcinoma or gastroesophageal junction… read more here.
Keywords: adverse events; apatinib; management apatinib; events management ... See more keywords